Interesting indeed, they just need money to start clinical trials Phase I/II this year 2026
CNBX Pharmaceuticals Inc. is a clinical stage pharmaceutical company primarily focused on the development of novel cannabinoid-based products and innovative technologies for the treatment of cancer.
Upon financing the company will prepare to launch Phase I/II (a) clinical study in 2026, for the evaluation of its lead drug candidates Cannabics SR for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) and RCC-33 for the treatment of colorectal cancer.
Our company’s core activities consist of:
· Drug Discovery: development of novel molecular formulations and drug candidates; · Intellectual Property: filing of corresponding IP to protect our products; and · Regulatory Affairs: initiation of the regulatory pathway for each drug candidate in our development pipeline
Our current business model is to undertake an FDA regulatory pathway for each of the new drug candidates under IND (Investigational New Drug) classification and complete a successful Phase I/II(a) clinical study (toxicity and proof of concept in humans). In reaching this milestone, where an initial feasibility in humans was demonstrated, the company will have gained several commercial opportunities for capitalizing on each such product candidate, including entering into commercial agreements with larger pharma corporations. Accordingly, our company does not engage in any manufacturing, distribution, or sales of products, nor is it foreseeable to expect that we will in the near future.
Market Data 
Markets 
AI
